SynthesisClinical otolaryngology : official journal of ENT-UK ; official journal of Netherlands Society for Oto-Rhino-Laryngology & Cervico-Facial Surgery2026
Inflammatory Myofibroblastic Tumour of Head and Neck: A Systematic Review Plus Meta-Analysis.
Synthesis in Clinical otolaryngology : official journal of ENT-UK ; official journal of Netherlands Society for Oto-Rhino-Laryngology & Cervico-Facial Surgery, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectivesThis systematic review with meta-analysis is aimed to examine clinical presentations, pathologic and imaging findings, treatment approaches, and prognosis of inflammatory myofibroblastic tumour.
methodsPubMed, Medline, Scopus, Cochrane Central Register of Control Trials, Web of Science, Google Scholar, and Embase were systematically searched up to February 2026. The search strategy was structured by a combination of relevant keywords and medical subheadings. This review adhered to Preferred Reporting Items for Systematic reviews and Meta-Analyses (PRISMA) guidelines and Population, Intervention, Comparison, and Outcome (PICO) statement.
resultsA total of 22 studies, including 337 patients, met the inclusion criteria. Most of the tumours originated from the sinonasal space (40.1%, proportion = 163), and the maxilla bone and hypopharynx had the least frequency (0.3%, proportion = 1). The most prevalent manifestations were proptosis and facial pain/swelling. Regarding immunohistochemical findings, tumours were mostly positive for vimentin and SMA, while they were commonly negative for desmin, S-100, anaplastic lymphoma kinase, and CD34. Many patients were treated with surgical resection alone without any recurrence occurring. Recurrence occurred in 21.6% (proportion = 67). Metastases occurred in 8.8% (proportion = 8).
conclusionsThe diagnosis of head and neck inflammatory myofibroblastic tumour appears related to the presence of vimentin, SMA, desmin, anaplastic lymphoma kinase, CD34, and S-100 on immunohistochemistry. The enhancement pattern on computed tomography cannot help diagnosis, but absence of calcification may distinguish tumour from other differential diagnoses. Surgical resection with a free margin is the most common treatment approach. Metastasis and malignant transformation rarely occur in this tumour of the head and neck region.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.